Treace Medical Concepts, Inc. (TMCI) AI Stock Analysis

Founded in 2013 and based in Ponte Vedra Beach, Florida, Treace Medical Concepts, Inc. designs, manufactures, and markets medical devices tailored for foot and ankle surgeons across the United States. Its flagship offering is the Lapiplasty procedure, which enables surgeons to address bunions in three dimensions for aesthetic and medical benefits. The company also offers the Lapiplasty Mini-Incision precision system to enhance surgical efficiency and precision. In addition, Treace provides ancillary products for various foot and ankle surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, and lesser tarsometatarsal joint fusions.

Treace expanded revenue from $94.4M in FY2021 to $212.7M in FY2025, delivering a 5-year revenue CAGR of 30.0%. However, annual growth slowed significantly over that period, dropping from 64.6% in FY2021, to 50.2% in FY2022, 31.9% in FY2023, 11.9% in FY2024, and 1.6% in FY2025. Gross margin remained consistent, shifting from 82.1% in FY2021 to 79.8% in FY2025. Net losses expanded over the period, moving from -$20.6M in FY2021 to -$59.0M in FY2025, with an operating margin of -25.5% in FY2025. In the latest quarter ended June 30, 2026, revenue fell 4.2% year-over-year, and trailing twelve months revenue stood at $205.3M with an operating margin of -33.0%.

As of June 30, 2026, Treace Medical Concepts held $45.6M in cash and short-term investments against total debt of $72.7M, resulting in net debt of $27.1M. The company maintains a current ratio of 2.90 and a debt-to-equity ratio of 1.07, supported by $67.7M in shareholders' equity and $181.1M in total assets. Operating cash flow in FY2025 was -$16.0M, and free cash flow was -$29.5M after capital expenditures of $13.5M. Additionally, the share count increased 21.3% over five years.

At a closing price of $3.87 on October 16, 2026, Treace Medical Concepts carried a market capitalization of $251.7M and an enterprise value of $320.1M. The stock trades at a price-to-sales multiple of 1.2x, below the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio is 4.3x. Over the past year, the stock fell 39.3%, trailing the S&P 500 return of 16.8%. Over five years, the stock declined 84.2% compared to an 83.0% gain for the S&P 500, although it has posted a year-to-date gain of 58.0%.

Wall Street analysts covering Treace Medical Concepts issue 1 Strong Buy, 3 Hold, and 1 Sell ratings. The mean price target of $5.50 represents a 42.1% premium over the last close of $3.87. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $207.5M and an EPS of -$0.85. For the following fiscal year, estimates project revenue of $221.7M and an EPS of -$0.85. The company exceeded EPS estimates in all 4 of its last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Treace Medical Concepts, Inc. (TMCI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TMCI income statement, TMCI balance sheet, TMCI key metrics, TMCI analyst forecast, TMCI chart. See the TMCI stock overview for the latest quote and news.